Latest News

Audentes commences dosing in Phase I/II trial for myotubular myopathy

US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM)....

Audentes commences dosing in Phase I/II trial for myotubular myopathy

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common...

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Cavion starts enrolment in Phase II trial of CX-8998 for essential tremor

US-based biotechnology firm Cavion has started patient enrolment in a Phase II clinical trial (T-CALM Study) of CX-8998 to treat essential tremor...

Cavion starts enrolment in Phase II trial of CX-8998 for essential tremor

Shire reports positive data from Phase III trial of Intuniv for ADHD

Shire reports positive data from Phase III trial of Intuniv for ADHD

Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer

Parker Institute begins dosing in Phase Ib/II combination trial for pancreatic cancer

Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers

Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic...

Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers

AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD

US-based pharmaceutical firm AgeneBio is set to investigate its therapeutic agent AGB101 in a Phase III clinical trial (HOPE4MCI) for the treatment of mild cognitive impairment due to...

AgeneBio to study AGB101 in Phase III trial to treat MCI due to AD

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL

Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis

Janssen Research & Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe...

Janssen reports positive long-term Phase III data of Tremfya for plaque psoriasis

Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial

Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure...

Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial

Sanofi and Regeneron report positive Phase III data from atopic dermatitis trial

Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial (CAFÉ) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis...

Sanofi and Regeneron report positive Phase III data from atopic dermatitis trial

Australian cancer centres launch personalised medicine trial for childhood cancers

Australian cancer centres launch personalised medicine trial for childhood cancers

Inovio launches Phase I/IIa trial for MERS infection in South Korea

US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in...

Inovio launches Phase I/IIa trial for MERS infection in South Korea

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

Novo Nordisk’s Tresiba minimises hypoglycaemia rate in diabetes trial

Denmark-based pharmaceutical firm Novo Nordisk has reported positive results from a clinical trial (DEVOTE) of Tresiba (insulin degludec) to treat patients with type 2...

Novo Nordisk’s Tresiba minimises hypoglycaemia rate in diabetes trial

Phrixus to study P-188 NF in Phase II trial to treat DMD

US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy...

Phrixus to study P-188 NF in Phase II trial to treat DMD

Deals this week: Synthetic Biologics, Bayer, HitGen

Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a...

Deals this week: Synthetic Biologics, Bayer, HitGen

M&As this week: inviCRO, Inotek Pharmaceuticals Corporation

inviCRO has completed the acquisition of UK-based translational research company...

M&As this week: inviCRO, Inotek Pharmaceuticals Corporation

Pfizer and Astellas report positive Phase III data from prostate cancer trial

Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat...

Pfizer and Astellas report positive Phase III data from prostate cancer trial

Tulane University reports favourable results from new malaria trial

Tulane University reports favourable results from new malaria trial

OncoMed begins dosing GITRL-Fc in Phase Ia trial for solid tumours

US-based OncoMed Pharmaceuticals has begun dosing patients in a Phase Ia clinical trial of its therapeutic candidate GITRL-Fc (OMP-336B11) to treat patients suffering from solid...

OncoMed begins dosing GITRL-Fc in Phase Ia trial for solid tumours
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_1016278895